Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 14, 2013; 19(14): 2154-2161
Published online Apr 14, 2013. doi: 10.3748/wjg.v19.i14.2154
Published online Apr 14, 2013. doi: 10.3748/wjg.v19.i14.2154
Table 5 Comparison of treatment approaches in the first and second series of treatments in metastatic gastric cancer patients
1st-series treatment approach | P value | 2nd-series treatment approach | P value |
DCF vs 5-FU-LV | 0.043 | DCF vs ECF | 0.050 |
DCF vs others | 0.010 | DCF vs Supportive | 0.042 |
DCF vs Supportive | < 0.001 | Supportive vs ECF | 0.500 |
DCF vs ECF | < 0.001 | DCF vs others | 0.605 |
DCF vs CF | 0.480 | Irinotecan/Cisp vs ECF | 0.423 |
ECF vs CF | 0.960 | Supportive vs Irinotecan/Cisp | 0.100 |
Supportive vs ECF | < 0.01 | DCF vs Irinotecan/Cisp | 0.672 |
- Citation: Selcukbiricik F, Buyukunal E, Tural D, Ozguroglu M, Demirelli F, Serdengecti S. Clinicopathological features and outcomes of patients with gastric cancer: A single-center experience. World J Gastroenterol 2013; 19(14): 2154-2161
- URL: https://www.wjgnet.com/1007-9327/full/v19/i14/2154.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i14.2154